Conclusion: Afatinib use was associated with a lower risk of progression in patients with NSCLC harboring EGFR mutations compared to gefitinib and erlotinib use. Concurrent use of systemic glucocorticoid showed higher progression risk.
showed higher progression risk. Methods: A549 cells were transduced with miR-21 shRNA and control shRNA. Cell proliferation, motility, cell cycle and apoptosis of transduced A549 cells were evaluated by CCK-8 assay, Cell-IQ live cell imaging analysis, scratch wound healing and flow cytometry, respectively.
The relative expression of miR-21 and PTEN mRNA was detected by RT-PCR. The expression levels of PTEN, phosphorylated Akt, PI3K and the downstream targets were detected by Western blotting.
Results: Down-regulation of miR-21 significantly reduced cell proliferation ( Fig.1) , migration ( Fig.2) and movement ( Fig.3 ) in A549 cells. In addition, down-regulation of miR-21 dramatically increased cell apoptosis (Fig.4 ) and blocked cell cycle at the G0/G1 and S phase (Fig.5 ). The expression of PTEN protein was increased when miR-21 was down-regulated, while the expression of PTEN mRNA did not change. The expression levels of phosphorylated Akt, PI3K and the related downstream targets were marked reduced or increased when miR-21 was downregulated (Fig.6) . 
Conclusion

